ABMD:NSD-Abiomed, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 217.36

Change

+9.60 (+4.62)%

Market Cap

USD 9.40B

Volume

0.80M

Average Target Price

USD 176.75 (-18.68%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company engages in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-2.23 (-0.89%)

USD19.80B 10.39 34.30
PODD Insulet Corporation

+6.15 (+3.45%)

USD12.08B 2,029.22 159.67
BRKR Bruker Corporation

-0.45 (-1.02%)

USD6.81B 36.70 19.38
LVGO Livongo Health, Inc

+4.45 (+8.33%)

USD5.38B N/A N/A
TNDM Tandem Diabetes Care, Inc

+0.88 (+1.07%)

USD4.95B N/A N/A
IART Integra LifeSciences Holdings ..

+0.06 (+0.12%)

USD4.42B 160.65 25.63
WMGI Wright Medical Group N.V

-0.12 (-0.40%)

USD3.85B N/A 41.56
NUVA NuVasive, Inc

-2.14 (-3.37%)

USD3.15B 54.64 14.87
SDC SmileDirectClub, Inc

-0.21 (-2.68%)

USD2.89B N/A N/A
LIVN LivaNova PLC

-0.96 (-1.74%)

USD2.66B 77.40 N/A

ETFs Containing ABMD

Symbol Name Weight Mer Price(Change) Market Cap
UTRN Vesper U.S. Large Cap Sho.. 4.55 % 0.75 %

+0.19 (+0.72%)

USD0.04B
SLIM The Obesity ETF 3.83 % 0.35 %

N/A

USD0.01B
JSMD Janus Henderson Small/Mid.. 2.31 % 0.35 %

-0.62 (-1.34%)

USD0.09B
RYH Invesco S&P 500 Equal Wei.. 1.90 % 0.40 %

+3.15 (+1.42%)

USD0.71B
HTEC Robo Global Healthcare Te.. 1.61 % 0.68 %

+0.34 (+1.15%)

USD0.01B
DWSH AdvisorShares Dorsey Wrig.. 1.45 % 3.07 %

+0.99 (+4.65%)

USD0.09B
PQLC PGIM QMA Strategic Alpha .. 0.43 % 0.17 %

-0.13 (-0.27%)

USD9.45M
TERM EquityCompass Tactical Ri.. 0.41 % 0.73 %

-0.06 (-0.40%)

USD0.02B
ERM EquityCompass Risk Manage.. 0.39 % 0.65 %

-0.07 (-0.42%)

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.42% 81% B- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.42% 81% B- 86% B
Trailing 12 Months  
Capital Gain -16.52% 53% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.52% 53% F 42% F
Trailing 5 Years  
Capital Gain 263.97% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 263.97% 92% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 40.31% 85% B 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.31% 85% B 93% A
Risk Return Profile  
Volatility (Standard Deviation) 68.45% 30% F 14% F
Risk Adjusted Return 58.89% 91% A- 83% B
Market Capitalization 9.40B 98% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 46.54 37% F 22% F
Price/Book Ratio 8.71 27% F 13% F
Price / Cash Flow Ratio 29.85 11% F 9% F
EV/EBITDA 32.73 33% F 18% F
Management Effectiveness  
Return on Equity 20.28% 95% A 90% A-
Return on Invested Capital 19.52% 92% A- 92% A-
Return on Assets 13.72% 98% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.72 34% F 28% F
Short Percent 7.67% 31% F 28% F
Beta 0.86 63% D 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.